To evaluate the efficacy and safety profile of rosuvastatin, simvastatin and atorvastatin in newly diagnosed type 2 diabetic patients with dyslipidaemia

https://doi.org/10.53730/ijhs.v6nS6.10585

Authors

  • Pravin Dhone Professor & Head, Department of Pharmacology, RSDKS GMC, Ambikapur
  • Rahul Gulati Professor & HOD, Department of medicine, Shri shankaracharya institute of medical sciences, junwani Bhilai District Durg CG
  • Padmini Sahu Assistant Professor, Department of Surgery, Bhima Bhoi Medical College and Hospital, Balangir
  • Mohd. Faheem Mubeen Associate Professor, Department of Pharmacology, Ayaan Institute Of Medical Science Hyderabad Corresponding Author

Keywords:

Rosuvastatin, Simvastatin, Atorvastatin, Type 2 Diabetic patients, Dyslipidaemia

Abstract

Dyslipidemia is one of the major risk factors for cardiovascular disease in diabetes mellitus. The lipid changes associated with diabetes mellitus are attributed to increased free fatty acid flux secondary to insulin resistance. Newly diagnosed 90 cases of patients of Type II Diabetes Mellitus well controlled on oral hypoglycemic drugs were randomly divided into 3 groups of 30 each. The mean difference of Triglycerides between baseline versus after 6 months was 65.04 mg/dl in Group A, 39.99 mg/dl in Group B and 37.04 mg/dl in Group C. The mean difference of HDL between baseline versus after 6 months was 10.04 mg/dl in Group A, 10.26 mg/dl in Group B and 9.13 mg/dl in Group C. The mean difference of LDL between baseline versus after 6 months was 79.4 mg/dl in Group A, 67.6 mg/dl in Group B and 33.82 mg/dl in Group C. The mean difference of VLDL between baseline versus after 6 months was 13.01 mg/dl in Group A, 7.58 mg/dl in Group B and 7.41 mg/dl in Group C. 

Downloads

Download data is not yet available.

References

Anjana RM, Pradeepa R, Deepa M, Datta M, Sudha V, Unnikrishnan R. ICMR–INDIAB Collaborative Study Group. Prevalence of diabetes and prediabetes (impaired fasting glucose and/or impaired glucose tolerance) in urban and rural India: Phase I results of the Indian Council of Medical Research India Diabetes (ICMR INDIAB) study. Diabetologia. 2011;54:3022-7.

Bobby D, Vinodha R. Dyslipidemia in type 2 diabetes mellitus – a major risk factor for cardiovascular morbidity. Int J Med Res Rev 2016;4(8):1387-1391.

Chen G, McAlister FA, Walker RL, Hemmelgarn BR, Campbell NR. Cardiovascular outcomes in framingham participants with diabetes: the importance of blood pressure. Hypertension. 2011 May;57(5):891-7.

Dixit AK, Dey R, Suresh A, Chaudhuri S, Panda AK, Mitra A, et al. The prevalence of dyslipidemia in patients with diabetes mellitus of ayurveda Hospital. J Diabet Metabol Disorders. 2014;13:58.

Farmer JA. Diabetic dyslipidemia and atherosclerosis: Evidence from clinical trials. Curr Diab Rep. 2008;8:71-7.

Firdous S, Khan MZ. Comparison of patterns of lipid profile in type-2 diabetics and nonraised diabetics. Ann King Edward Med Coll. 2007;3(1):84-7.

Gavin JR 3rd. Reducing global cardiovascular risk in patients with type 2 diabetes mellitus. J Am Osteopath Assoc. 2008 May;108(5 Suppl 3):S14-9.

Gokcel A, Karakose H, Ertorer EM, Tanaci N, Tutuncu NB, Guvener N. Effects of sibutramine in obese female subjects with type 2 diabetes and poor blood glucose control. Diabetes Care. 2001 Nov;24(11):1957-60.

Janghorbani M., Amini M. Incidence of metabolic syndrome and its risk factors among type 2 diabetes clinic attenders in Isfahan, Iran. ISRN Endocrinol. 2012;2012:167318.

Jayarama N, Reddy M, Lakshmaiah V. Prevalence and pattern of dyslipidemia in type 2 diabetes mellitus patients in a rural tertiary care centre, southern India. Glob J Med Public Health 2012;1:24-8.

Jellinger PS, Smith DA, Mehta AE, Ganda O, Handelsman Y, Rodbard HW, et al. American association of clinical endocrinologists' guidelines for management of Dyslipidemia and prevention of atherosclerosis. Endocr Pract 2012;18 Suppl 1:1-78.

Keech A, Colquhoun D, Best J, Kirby A, Simes RJ, Hunt D, Hague W, Beller E, Arulchelvam M, Baker J, Tonkin A; LIPID Study Group. Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial. Diabetes Care. 2003 Oct;26(10):2713-21.

Keech A, Colquhoun D, Best J, Kirby A, Simes RJ, Hunt D. LIPID Study Group. Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial. Diabetes care. 2003;26(10):2713-21.

Kengne A.P., Limen S.N., Sobngwi E. Metabolic syndrome in type 2 diabetes: comparative prevalence according to two sets of diagnostic criteria in sub-Saharan Africans. Diabetol Metab Syndr. 2012 May 31;4(1):22.

Krauss RM. Lipids and lipoproteins in patients with type 2 diabetes. Diabet Care. 2004;27:1496-504.

Mahato RV, Gyawali P, Raut PP, Regmi P, Singh PK, Pandey DR, et al. Association between glycaemic control and serum lipid profile in type 2 diabetic patients: glycated haemoglobin as a dual biomarker. Biomed Res. 2011;22(3):375-80.

Marjani A., Shirafkan A. The metabolic syndrome in type 2 diabetic patients in Gorgan: according to NCEP ATPIII and IDF definitions. Diabetes Metabol Syndr: Clin Res Rev. 2011 Apr;5(4):207–210.

Masram SW, Bimanpalli MV, Ghangle, S. Study of lipid profile and glycated hemoglobin in Diabetes mellitus. Indian Medical Gazette. 2012;257-65.

Misra A, Pandey RM, Devi JR, Sharma R, Vikram NK, Khanna N. High prevalence of diabetes, obesity and dyslipidaemia in urban slum population in northern India. Int J Obes Relat Metab Disord. 2001;25:1722-9.

Mohan V, Sandeep S, Deepa R, Shah B, Varghese C. Epidemiology of type 2 diabetes: Indian scenario. Indian J Med Res. 2007;125:217-30.

Osuji C.U., Nzerem B.A., Dioka C.E. Metabolic syndrome in newly diagnosed type 2 diabetes mellitus using NCEP-ATPIII, the Nnewi experience. Niger J Clin Pract. 2012 Oct–Dec;15(4):475–480.

Pandya H, Lakhani JD, Dadhania J, Trivedi A. The prevalence and pattern of dyslipidemia among type 2 diabetic patients at rural based hospital in Gujarat, India. J Clin Prac. 2012;22(12):36-44.

Parikh RM, Joshi SR, Menon PS, Shash NS. Prevalence and Pattern of Diabetic Dyslipidemia in Indian type 2 Diabetic patients. Diabetes and Metabolic Syndrome. Clinical Research and Review. 2010;4(1):10-12.

Rani HS, Madhavi G, Rao VR, Sahay BK, Jyothy A. Risk factors for coronary heart disease in type II diabetes mellitus. Indian J Clin Biochem. 2005;20(2):75-80.

Samatha P, Venkateswarlu M, Siva Prabodh V. Lipid profile levels in type 2 diabetes mellitus from tribal population of Adilabad in Andhra Pradesh, India. J Clin Diagnostic Res. 2012;6(4):590-2.

Selvin E, Coresh J, Golden SH, Boland LL, Brancati FL, Steffes MW; Atherosclerosis risk in communities study. Glycemic control, atherosclerosis, and risk factors for cardiovascular disease in individuals with diabetes: the atherosclerosis risk in communities study. Diabetes Care. 2005 Aug;28(8):1965-73.

Smith S, Lall AM. A Study on Lipid Profile Levels of Diabetics and Non-Diabetics Among Naini Region of Allahabad, India. Turk J Biochem. 2008;33(4):138-41.

Sunarmi, A., Haksari, E. L., & Fitriahadi, E. (2022). Childbirth counseling by WhatsApp group to reduce the anxiety of primigravida. International Journal of Health & Medical Sciences, 5(3), 193-200. https://doi.org/10.21744/ijhms.v5n3.1905

Suryasa, I. W., Rodríguez-Gámez, M., & Koldoris, T. (2021). Get vaccinated when it is your turn and follow the local guidelines. International Journal of Health Sciences, 5(3), x-xv. https://doi.org/10.53730/ijhs.v5n3.2938

Taylor HA Jr, Akylbekova EL, Garrison RJ, Sarpong D, Joe J, Walker E, Wyatt SB, Steffes MW. Dyslipidemia and the treatment of lipid disorders in African Americans. Am J Med. 2009 May;122(5):454-63.

Unnikrishnan R, Anjana RM, Mohan V. Diabetes mellitus and its complications in India. Nat Rev Endocrinol. 2016;12(6):357–370.

Uttra KM, Devrajani BR, Shah SZA, Devrajani T, Das T, Raza S, et al. Lipid Profile of Patients with Diabetes mellitus. World Appl Sci. 2011;J12(9):1382-4

Widana, I.K., Sumetri, N.W., Sutapa, I.K., Suryasa, W. (2021). Anthropometric measures for better cardiovascular and musculoskeletal health. Computer Applications in Engineering Education, 29(3), 550–561. https://doi.org/10.1002/cae.22202

Published

12-07-2022

How to Cite

Dhone , P., Gulati, R., Sahu, P., & Mubeen, M. F. (2022). To evaluate the efficacy and safety profile of rosuvastatin, simvastatin and atorvastatin in newly diagnosed type 2 diabetic patients with dyslipidaemia. International Journal of Health Sciences, 6(S6), 1213–1221. https://doi.org/10.53730/ijhs.v6nS6.10585

Issue

Section

Peer Review Articles